1-20 of 34
Joel S. Parker
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract PO2-15-08: Exploring Essential Immune Genes Linked to Pathological Complete Response and Survival in Early-Stage Triple-Negative Breast Cancer (TNBC) after Chemotherapy Treatment

Fara Brasó-Maristany, Laia Paré, Benedetta Conte, Laura Angelats, Ana Vivancos, Joel S Parker, Charles M. Perou, Patricia Villagrasa, Aleix Prat
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO2-15-08.
https://doi.org/10.1158/1538-7445.SABCS23-PO2-15-08
Published: 02 May 2024
View article titled, Abstract PO2-15-08: Exploring Essential Immune Genes Linked to Pathological Complete Response and Survival in Early-Stage Triple-Negative Breast Cancer (TNBC) after Chemotherapy Treatment
Journal Articles

Abstract PO2-15-07: HER2DX genomic assay in triple-negative breast cancer (TNBC) patients treated with 12-weeks of neoadjuvant chemotherapy: a correlative analysis from WSG-ADAPT-TN phase II trial

Oleg Gluz, Fara Brasó-Maristany, Ulrike Nitz, Laia Paré, Matthias Christgen, Guillermo Villacampa, Benedetta Conte, Sherko Kuemmel, Ronald Kates, Cornelia Kolberg-Liedtke, Eva-Maria Grischke, Helmut Forstbauer, Michael Braun, Mathias Warm, John Hackmann, Christoph Uleer, Bahriye Aktas, Claudia Schumacher, Ana Vivancos, Rachel Wuerstlein, Joel S. Parker, Monika Graeser, Charles M. Perou, Christine zu Eulenburg, Patricia Villagrasa, Hans-Heinrich Kreipe, Aleix Prat, Nadia Harbeck
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO2-15-07.
https://doi.org/10.1158/1538-7445.SABCS23-PO2-15-07
Published: 02 May 2024
View article titled, Abstract PO2-15-07: HER2DX genomic assay in triple-negative breast cancer (TNBC) patients treated with 12-weeks of neoadjuvant chemotherapy: a correlative analysis from WSG-ADAPT-TN phase II trial
Journal Articles

Abstract PO2-15-06: ctDNA-based DNADX in hormone receptor-positive and HER2-negative (HR+/HER2-) advanced breast cancer following endocrine therapy and CDK4/6 inhibition: a correlative analysis from the randomized phase 2 PARSIFAL trial

Fara Brasó-Maristany, Javier Cortés, José Manuel Pérez-García, Rosario Vega-León, Laia Paré, Guillermo Villacampa, Judit Matito, Francisco Pardo, Marina Gomez-Rey, Mario Mancino, Elena Martínez-García, Carmen Mora Gallardo, Leonardo Mina, Florence Dalenc, Meritxell Bellet- Ezquerra, Manuel Ruíz - Borrego, Miguel Gil-Gil, Peter Schmid, Charles M. Perou, Joel S. Parker, Patricia Villagrasa, Ana Vivancos, Aleix Prat, Antonio Llombart-Cussac
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO2-15-06.
https://doi.org/10.1158/1538-7445.SABCS23-PO2-15-06
Published: 02 May 2024
View article titled, Abstract PO2-15-06: ctDNA-based DNADX in hormone receptor-positive and HER2-negative (HR+/HER2-) advanced breast cancer following endocrine therapy and CDK4/6 inhibition: a correlative analysis from the randomized phase 2 PARSIFAL trial
Journal Articles

Abstract PO3-16-03: Investigating HER2DX genomic assay concordance within HER2-positive breast cancer

Fara Brasó-Maristany, Laia Paré, Guillermo Villacampa, Mercedes Marín-Aguilera, Paul Spellman, Adrienne Waks, Ian Krop, Esther Sanfeliu, Zhequi Li, Patricia Galván, Eva Hernández-Illán, Pedro Jares, Joan Antón Puig-Butillé, Ana Vivancos, Patricia Villagrasa, Joel S. Parker, Charles M. Perou, Sara Tolaney, Otto Metzger, Kornelia Polyak, Aleix Prat
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO3-16-03.
https://doi.org/10.1158/1538-7445.SABCS23-PO3-16-03
Published: 02 May 2024
View article titled, Abstract PO3-16-03: Investigating HER2DX genomic assay concordance within HER2-positive breast cancer
Journal Articles

Abstract 5754: Determining the regulatory logic of breast cancer cells using single-cell multi-omics

Matthew J. Regner, Aatish Thennavan, Susana Garcia-Recio, Kamila Wisniewska, Philip M. Spanheimer, Joel S. Parker, Charles M. Perou, Hector L. Franco
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 5754.
https://doi.org/10.1158/1538-7445.AM2023-5754
Published: 04 April 2023
View article titled, Abstract 5754: Determining the regulatory logic of breast cancer cells using single-cell multi-omics
Journal Articles

Abstract PD9-06: Histopathological and molecular immune landscape and DNA damage response signatures to predict response to carboplatin and docetaxel in TNT trial TNBC cohort

Holly Tovey, Orsolya Sipos, Katherine A Hoadley, Joel S Parker, Jelmar Quist, Sarah Kernaghan, Lucy Kilburn, Roberto Salgado, Sherene Loi, Richard D Kennedy, Ioannis Roxanis, Patrycja Gazinska, Sarah E. Pinder, Judith Bliss, Charles M. Perou, Syed Haider, Andrew Tutt, Anita Grigoriadis, Maggie Chon U Cheang
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): PD9-06.
https://doi.org/10.1158/1538-7445.SABCS22-PD9-06
Published: 01 March 2023
View article titled, Abstract PD9-06: Histopathological and molecular immune landscape and DNA damage response signatures to predict response to carboplatin and docetaxel in TNT trial TNBC cohort
Journal Articles

Abstract P4-02-30: Association between tumor infiltrating lymphocytes (TILs) and the HER2DX assay in early-stage of HER2-positive (HER2+) breast cancer

Esther Sanfeliu, Fara Brasó-Maristany, Maria Vittoria Dieci, Mercedes Marín-Aguilera, Blanca González-Farré, Gaia Griguolo, Tomas Pascual, Patricia Galván, Laura Angelats, Oleguer Castillo, Paula Blasco, Valeria Sirenko, Pedro Jares, Joan Antón Puig-Butillé, Laia Paré, Antonio Martínez, Antonio Llombart-Cussac, Javier Cortés, Ana Vivancos, Patricia Villagrasa, Joel S Parker, Charles M Perou, Aleix Prat, PierFranco Conte, Valentina Guarneri
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P4-02-30.
https://doi.org/10.1158/1538-7445.SABCS22-P4-02-30
Published: 01 March 2023
View article titled, Abstract P4-02-30: Association between tumor infiltrating lymphocytes (TILs) and the HER2DX assay in early-stage of HER2-positive (HER2+) breast cancer
Journal Articles

Abstract P1-04-05: Independent validation of the HER2DX genomic test in HER2-positive breast cancer treated with neoadjuvant paclitaxel, trastuzumab and pertuzumab (THP): a correlative analysis from the DAPHNe phase II clinical trial

Adrienne Waks, Esther R. Ogayo, Laia Paré, Mercedes Marín-Aguilera, Fara Brasó-Maristany, Patricia Galván, Oleguer Castillo, Olga Martínez-Sáez, Ana Vivancos, Patricia Villagrasa, Paolo Tarantino, Neelam Desai, Jennifer Guerriero, Otto Metzger, Nadine Tung, Ian Krop, Joel S Parker, Charles M. Perou, Aleix Prat, Eric Winer, Sara Tolaney, Elizabeth A. Mittendorf
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P1-04-05.
https://doi.org/10.1158/1538-7445.SABCS22-P1-04-05
Published: 01 March 2023
View article titled, Abstract P1-04-05: Independent validation of the HER2DX genomic test in HER2-positive breast cancer treated with neoadjuvant paclitaxel, trastuzumab and pertuzumab (THP): a correlative analysis from the DAPHNe phase II clinical trial
Journal Articles

Abstract P6-01-46: Independent validation of the HER2DX genomic test in HER2-positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab +/- pertuzumab (TCH/TCHP): a correlative analysis from a multicenter academic study

Coralia Bueno-Muiño, Isabel Echavarria, Sara López-Tarruella, Roche-Molina Marta, María del Monte-Millán, Tatiana Massarrah, Yolanda Jerez Gilarranz, Blanca Herrero, Salvador Gámez, Iván Márquez-Rodas, María Cebollero-Presmanes, Nevado Santos Manuel, Pilar de la Morena Barrio, Francisco Ayala de la Peña, José Ángel García-Sáenz, Fernando Moreno Antón, Álvaro Rodríguez Lescure, Teresa Quintanar, Diego Malón-Giménez, Laura Rodriguez-Lajusticia, Ana Isabel Ballesteros García, Dulce Bañón Torres, Lucía Villarejo, Nerea Lobato, Ainhoa Arias, Inmaculada Ocaña, Enrique Álvarez, Laia Paré, Mercedes Marín-Aguilera, Patricia Galván, Fara Brasó-Maristany, Ana Vivancos, Patricia Villagrasa, Joel S Parker, Charles M. Perou, Aleix Prat, Miguel Martín
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P6-01-46.
https://doi.org/10.1158/1538-7445.SABCS22-P6-01-46
Published: 01 March 2023
View article titled, Abstract P6-01-46: Independent validation of the HER2DX genomic test in HER2-positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab +/- pertuzumab (TCH/TCHP): a correlative analysis from a multicenter academic study
Journal Articles

Abstract PS18-12: Comparative analysis of differential gene expression by ancestry using primary breast cancers from Nigeria and the cancer genome atlas (TCGA)

Padma Sheila Rajagopal, Yi-Hsuan S Tsai, Ashley Hardeman, Ian Hurley, Aminah Sallam, Yonglan Zheng, Toshio Yoshimatsu, Anna Woodard, Dezheng Huo, Guimin Gao, Charles M Perou, Joel S Parker, Mengjie Chen, Olufunmilayo I Olopade
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PS18-12.
https://doi.org/10.1158/1538-7445.SABCS20-PS18-12
Published: 15 February 2021
View article titled, Abstract PS18-12: Comparative analysis of differential gene expression by ancestry using primary breast cancers from Nigeria and the cancer genome atlas (TCGA)
Journal Articles

Abstract GS3-08: Multiplatform analysis of matched primary and metastatic breast tumors from the AURORA US Network

Tari A King, Minetta C Liu, Marni B McClure, Toshinori Hinoue, Benjamin J Kelly, Chad J Creighton, Jay Bowen, Kristen Leraas, Robyn T Burns, Sara Coppens, Salma Rezk, Amy L Garrett, Justin M Balko, Joel S Parker, Ben H Park, Ian Krop, Carey Anders, Katherine A Hoadley, Julie Gastier-Foster, Mothaffar F Rimawi, Rita Nanda, Nancy U Lin, Claudine Isaacs, P. Kelly Marcom, Anna Maria Storniolo, Fergus J Couch, Elaine R Mardis, Adrian V Lee, Uma Chandran, Peter W Laird, Susan G Hilsenbeck, Larry Norton, Andrea L Richardson, W. Fraser Symmans, Lisa A Carey, Antonio C Wolff, Nancy E Davidson, Charles M Perou, the AURORA US Network
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): GS3-08.
https://doi.org/10.1158/1538-7445.SABCS19-GS3-08
Published: 15 February 2020
View article titled, Abstract GS3-08: Multiplatform analysis of matched primary and metastatic breast tumors from the AURORA US Network
Journal Articles

Abstract P4-05-12: Genetic determinants of the molecular portraits of epithelial cancers

Youli Xia, Cheng Fan, Katherine A Hoadley, Joel S Parker, Charles M Perou
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P4-05-12.
https://doi.org/10.1158/1538-7445.SABCS19-P4-05-12
Published: 15 February 2020
View article titled, Abstract P4-05-12: Genetic determinants of the molecular portraits of epithelial cancers
Journal Articles

Abstract 1678: Accurate detection of expressed variation in RNA-seq

Lisle E. Mose, David Marron, Joel S. Parker
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 1678.
https://doi.org/10.1158/1538-7445.AM2019-1678
Published: 01 July 2019
View article titled, Abstract 1678: Accurate detection of expressed variation in RNA-seq
Journal Articles

Abstract 4318: Identifying drivers of SMARCA4/BRG1-deficient SCCOHT tumorigenesis by integrative multi-omic analysis

Krystal A. Orlando, Jesse R. Raab, Jessica D. Lang, William P. Hendricks, Yemin Wang, David G. Huntsman, Jeffrey M. Trent, Joel S. Parker, Bernard E. Weissman
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 4318.
https://doi.org/10.1158/1538-7445.AM2018-4318
Published: 01 July 2018
View article titled, Abstract 4318: Identifying drivers of SMARCA4/BRG1-deficient SCCOHT tumorigenesis by integrative multi-omic analysis
Journal Articles

SETD2 Haploinsufficiency for Microtubule Methylation Is an Early Driver of Genomic Instability in Renal Cell Carcinoma

Yun-Chen Chiang, In-Young Park, Esteban A. Terzo, Durga Nand Tripathi, Frank M. Mason, Catherine C. Fahey, Menuka Karki, Charles B. Shuster, Bo-Hwa Sohn, Pratim Chowdhury, Reid T. Powell, Ryoma Ohi, Yihsuan S. Tsai, Aguirre A. de Cubas, Abid Khan, Ian J. Davis, Brian D. Strahl, Joel S. Parker, Ruhee Dere, Cheryl L. Walker, W. Kimryn Rathmell
Journal: Cancer Research
Cancer Res (2018) 78 (12): 3135–3146.
https://doi.org/10.1158/0008-5472.CAN-17-3460
Published: 14 June 2018
View article titled, <em>SETD2</em> Haploinsufficiency for Microtubule Methylation Is an Early Driver of Genomic Instability in Renal Cell Carcinoma
Open the PDF for <em>SETD2</em> Haploinsufficiency for Microtubule Methylation Is an Early Driver of Genomic Instability in Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Immune-Related Gene Expression Profiling After PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma

Aleix Prat, Alejandro Navarro, Laia Paré, Noemí Reguart, Patricia Galván, Tomás Pascual, Alex Martínez, Paolo Nuciforo, Laura Comerma, Llucia Alos, Nuria Pardo, Susana Cedrés, Cheng Fan, Joel S. Parker, Lydia Gaba, Iván Victoria, Nuria Viñolas, Ana Vivancos, Ana Arance, Enriqueta Felip
Journal: Cancer Research
Cancer Res (2017) 77 (13): 3540–3550.
https://doi.org/10.1158/0008-5472.CAN-16-3556
Published: 02 July 2017
View article titled, Immune-Related Gene Expression Profiling After PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma
Open the PDF for Immune-Related Gene Expression Profiling After PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma in another window
Includes: Supplementary data
Journal Articles

Abstract 568: Regulatory T cell recruitment limits the effectiveness of checkpoint inhibition for claudin-low breast cancer

Sarah C. Vick, Nicholas A. Taylor, Michael D. Iglesia, W June Brickey, Lisa A. Carey, Bentley R. Midkiff, Karen P. McKinnon, Shannon Reisdorf, Joel S. Parker, Charles M. Perou, Benjamin G. Vincent, Jonathan S. Serody
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 568.
https://doi.org/10.1158/1538-7445.AM2017-568
Published: 01 July 2017
View article titled, Abstract 568: Regulatory T cell recruitment limits the effectiveness of checkpoint inhibition for claudin-low breast cancer
Journal Articles

Abstract 3592: Improved indel detection in RNA-seq data via assembly based re-alignment reveals expressed Epidermal Growth Factor Receptor indels in Lung Adenocarcinoma

Lisle E. Mose, D. Neil Hayes, Charles M. Perou, Joel S. Parker
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 3592.
https://doi.org/10.1158/1538-7445.AM2017-3592
Published: 01 July 2017
View article titled, Abstract 3592: Improved indel detection in RNA-seq data via assembly based re-alignment reveals expressed Epidermal Growth Factor Receptor indels in Lung Adenocarcinoma
Journal Articles

Abstract 3119: Identification of genetic drivers in HER2enriched/HER2negative breast cancer

Susana Garcia Recio, Cheng Fan, Marni Siegel, Joel S. Parker, Gina N. Duronio, Aleix Prat, Charles M. Perou
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 3119.
https://doi.org/10.1158/1538-7445.AM2017-3119
Published: 01 July 2017
View article titled, Abstract 3119: Identification of genetic drivers in HER2enriched/HER2negative breast cancer
Journal Articles

Abstract 4499: Integration of targeted RNA sequencing to targeted DNA sequencing for the characterization of clinically relevant variants in a population of thousands of patients treated on clinical trial

Woochang Lee, Heejoon Jo, Xiaoying Yin, David A. Eberhard, Nirali M. Patel, Michele C. Hayward, Ashley H. Salazar, Joel S. Parker, William Y. Kim, Henry S. Earp, Norman E. Sharpless, David N. Hayes
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 4499.
https://doi.org/10.1158/1538-7445.AM2016-4499
Published: 15 July 2016
View article titled, Abstract 4499: Integration of targeted RNA sequencing to targeted DNA sequencing for the characterization of clinically relevant variants in a population of thousands of patients treated on clinical trial